Ballentine Partners LLC Lowers Holdings in Repligen Co. (NASDAQ:RGEN)

Ballentine Partners LLC trimmed its holdings in Repligen Co. (NASDAQ:RGEN) by 35.7% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,702 shares of the biotechnology company’s stock after selling 947 shares during the quarter. Ballentine Partners LLC’s holdings in Repligen were worth $215,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in RGEN. Acadian Asset Management LLC purchased a new position in Repligen during the second quarter valued at $157,000. Norden Group LLC boosted its holdings in shares of Repligen by 32.2% during the 2nd quarter. Norden Group LLC now owns 3,930 shares of the biotechnology company’s stock valued at $495,000 after purchasing an additional 958 shares during the last quarter. North Star Asset Management Inc. grew its position in shares of Repligen by 1.6% during the second quarter. North Star Asset Management Inc. now owns 93,724 shares of the biotechnology company’s stock valued at $11,815,000 after purchasing an additional 1,518 shares in the last quarter. TD Asset Management Inc increased its holdings in shares of Repligen by 2.1% in the second quarter. TD Asset Management Inc now owns 58,965 shares of the biotechnology company’s stock worth $7,433,000 after purchasing an additional 1,233 shares during the last quarter. Finally, Roubaix Capital LLC purchased a new stake in shares of Repligen in the second quarter worth about $1,767,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Trading Down 1.0 %

RGEN opened at $141.93 on Friday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.56 and a current ratio of 6.65. The stock’s 50 day moving average price is $144.61 and its 200-day moving average price is $157.83. Repligen Co. has a one year low of $110.45 and a one year high of $211.13. The stock has a market cap of $7.95 billion, a price-to-earnings ratio of 568.58, a P/E/G ratio of 4.35 and a beta of 0.94.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported $0.33 EPS for the quarter, meeting the consensus estimate of $0.33. Repligen had a positive return on equity of 3.36% and a negative net margin of 0.32%. The company had revenue of $154.07 million for the quarter, compared to the consensus estimate of $154.11 million. During the same quarter in the prior year, the company posted $0.53 EPS. Repligen’s quarterly revenue was down 3.2% on a year-over-year basis. On average, equities analysts forecast that Repligen Co. will post 1.45 EPS for the current year.

Insider Activity at Repligen

In other Repligen news, VP Ralf Kuriyel sold 4,465 shares of the company’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $165.67, for a total value of $739,716.55. Following the transaction, the vice president now directly owns 19,261 shares in the company, valued at approximately $3,190,969.87. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, VP Ralf Kuriyel sold 4,465 shares of the stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $165.67, for a total value of $739,716.55. Following the transaction, the vice president now owns 19,261 shares of the company’s stock, valued at $3,190,969.87. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Anthony Hunt sold 22,191 shares of the firm’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the transaction, the director now owns 139,840 shares in the company, valued at $20,328,540.80. The disclosure for this sale can be found here. 1.20% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of analysts have issued reports on the company. UBS Group reduced their price objective on Repligen from $205.00 to $185.00 and set a “buy” rating on the stock in a research note on Wednesday, July 31st. Wells Fargo & Company began coverage on shares of Repligen in a research note on Tuesday, August 27th. They set an “overweight” rating and a $180.00 price target on the stock. Stephens restated an “overweight” rating and issued a $170.00 target price on shares of Repligen in a report on Tuesday, July 30th. Benchmark restated a “hold” rating on shares of Repligen in a research report on Monday, August 5th. Finally, JPMorgan Chase & Co. boosted their price objective on Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 31st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $188.38.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.